Inotiv, Inc. (NOTV)

US — Healthcare Sector
Peers: FONR  BNR  SERA  OLK  LMDX  GTH  XGN  SHC  DRIO  STIM  MDXH 

Automate Your Wheel Strategy on NOTV

With Tiblio's Option Bot, you can configure your own wheel strategy including NOTV - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol NOTV
  • Rev/Share 14.1315
  • Book/Share 4.6387
  • PB 0.4678
  • Debt/Equity 0.1023
  • CurrentRatio 1.5047
  • ROIC -0.0685

 

  • MktCap 74546010.0
  • FreeCF/Share -1.5925
  • PFCF -1.377
  • PE -0.8433
  • Debt/Assets 0.0211
  • DivYield 0
  • ROE -0.5145

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 4
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Inotiv, Inc. (NOTV) Q2 2025 Earnings Call Transcript
NOTV
Published: May 08, 2025 by: Seeking Alpha
Sentiment: Neutral

Call Start: 16:30 January 1, 0000 5:20 PM ET Inotiv, Inc. (NASDAQ:NOTV ) Q2 2025 Earnings Conference Call May 7, 2025, 04:30 PM ET Company Participants Steve Halper - Investor Relations Bob Leasure - President and Chief Executive Officer Beth Taylor - Chief Financial Officer John Sagartz - Chief Strategy Officer Conference Call Participants Matt Hewitt - Craig-Hallum Capital Group Nelson Cox - Lake Street Capital Markets Dave Windley - Jefferies Operator Good day, everyone, and welcome to today's Inotiv Second Quarter Fiscal 2025 Earnings Call. [Operator Instructions] Please note, today's call will be recorded and I will be standing …

Read More
image for news Inotiv, Inc. (NOTV) Q2 2025 Earnings Call Transcript
Inotiv, Inc. (NOTV) Reports Q2 Loss, Tops Revenue Estimates
NOTV
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Negative

Inotiv, Inc. (NOTV) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.29 per share a year ago.

Read More
image for news Inotiv, Inc. (NOTV) Reports Q2 Loss, Tops Revenue Estimates

About Inotiv, Inc. (NOTV)

  • IPO Date 1997-11-25
  • Website https://www.inotivco.com
  • Industry Medical - Diagnostics & Research
  • CEO Mr. Robert W. Leasure Jr.
  • Employees 1977
Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It has an agreement with BioVaxys to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.